Skip to main content

Table 5 Base-case costs and health outcomes results

From: Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

 

EDB

HUK

QALYs

7.621

7.468

Costs

¥28,687

¥27,832

 Drug costs

¥2,772

¥2,100

 Hospitalization costs

¥18,116

¥18,005

 Post-stroke costs

¥7,799

¥7,727

NMB

¥588,426

¥576,927

Incremental costs

¥856

Incremental QALYs

0.153

Incremental NMB

¥11,499

ICER

¥5,608

  1. ICER Incremental cost-effectiveness ratio, NMB Net monetary benefit, QALY Quality-adjusted life year